Zentalis Pharmaceuticals Inc. (ZNTL)
NASDAQ: ZNTLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZNTL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $133.64M
- EPS (TTM)
- -$1.90
- Dividend yield
- None
- 52-week range
- 1.30 – 6.95
- Day range
- 1.33 – 1.50
- Volume / Avg
- 1.46M / 1.26M
- Beta
- —
- Shares outstanding
- 98.27M
52-week range
ZNTL stock today
Zentalis Pharmaceuticals (ZNTL) closed at $1.36 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. At this level, ZNTL sits near the bottom of its 52-week range of $1.30 to $6.95: 80.4% below the high, set on Apr 10, 2026 and 4.6% above the low. ZNTL is up 0.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.5%.
Zentalis Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.90), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Zentalis Pharmaceuticals
Company profileZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Julie M. Eastland M.B.A.
- Headquarters
- San Diego, CA
- Employees
- 106
- IPO year
- 2020
- Website
- zentalis.com
Financial highlights
Full financialsIn fiscal 2025, Zentalis Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, the first decline in the 7 years shown. Zentalis Pharmaceuticals reported a net loss of $137.1 million, compared with a loss of $165.8 million a year earlier. Diluted earnings per share came in at -$1.91.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $67.42M | $0 | $0 | — |
| Growth | -100.00% | — | — | — | — |
| Net income | $-137.06M | $-165.84M | $-292.19M | $-236.81M | $-158.72M |
| EPS (diluted) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$7.44+447.06%
- Strong buy 0
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.34 vs $-0.58
- Surprise
- +41.38%
ZNTL news
All ZNTL news- Zentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026GlobeNewswire
- Zentalis Reports Interim OS Rates Of 15 Months In Cyclin-E1 PROC Patients Treated With AzenosertibNasdaqZNTL, DDS
- Zentalis Highlights Interim Survival Data From DENALI Part 1b Study Of Azenosertib In PROCNasdaqZNTL, ET
- Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractGlobeNewswire
Zentalis Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALXOALX Oncology Holdings Inc. | 1.06 | +3.92% | $137.03M | vs ZNTL |
| SIONSionna Therapeutics Inc. | 2.83 | -4.88% | $127.79M | vs ZNTL |
| MGNXMacroGenics Inc. | 1.96 | -1.01% | $125.26M | vs ZNTL |
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.81 | -2.69% | $145.25M | vs ZNTL |
| MSLESatellos Bioscience Inc. | 5.68 | -2.07% | $120.51M | vs ZNTL |
| PRQRProQR Therapeutics N.V. | 1.04 | -0.95% | $146.98M | vs ZNTL |
| VRXAVeraxa Biotech AG | 1.04 | +0.97% | $147.06M | vs ZNTL |
| ADAGAdagene Inc. ADR | 1.76 | -12.44% | $118.17M | vs ZNTL |
Indexes, lists and sector
Zentalis Pharmaceuticals stock FAQ
What is Zentalis Pharmaceuticals's stock price today?
ZNTL last traded at $1.36 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.
Who is Zentalis Pharmaceuticals's CEO?
Ms. Julie M. Eastland M.B.A. is the chief executive officer of Zentalis Pharmaceuticals Inc., which has about 106 employees.
What is the ZNTL 52-week high?
The 52-week high for ZNTL is $6.95 and the 52-week low is $1.30. The stock is currently 80.4% below its high.